The life sciences industry has made significant progress in creating more inclusive clinical trials over the past 20 years. But as our country becomes more diverse, it’s even more important to recruit populations that reflect the underlying patient demographics of the disease being studied.

Building diversity in clinical trials involves an understanding of socioeconomic inequities, health disparities, and the reasons behind decades of mistrust among certain groups. They must also recognize and address the cause of patient recruitment issues that have plagued clinical trials for years.

This article provides insights and data to help sponsors and CROs work through the interrelated reasons behind the lack of clinical trial diversity. With appropriately diverse sample sizes, trials are better positioned to develop treatments and dosages that work well for everyone.

Read the article to discover:

  • The therapeutic areas that consistently underrepresent minority populations
  • Why expanding globally isn’t the best solution
  • How to start: building awareness and trust
  • Why patient-centric practices work for all study populations
  • Technology that can help you reach your goals